Hungarian drug maker Gedeon Richter’s consolidated Q4 after-tax profit jumped 136.4 pct to HUF 15.9 billion from the same period a year earlier.
Hungarian drug maker Gedeon Richter’s consolidated Q4 after-tax profit jumped 136.4 pct to HUF 15.9 billion from the same period a year earlier boosted by higher sales and a manifold rise in financial income, the company’s report for the period, published on February 11, shows.
Profits were in line with an estimate by analysts polled by portfolio.hu.
Q4 diluted earnings per share rose to HUF 860 from HUF 362 in the same period a year earlier.
Sales revenue increased 15.6 pct to HUF 65.1 billion. Cost of sales rose at a slower rate, climbing 24.8 pct to HUF 32.1 billion. Gross profit rose 8.5 pct to HUF 33.2 billion.
